As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.

The study in Nature Medicine reveals that alongside weight loss benefits, GLP-1 medications like Ozempic and Mounjaro may pose heightened risks for kidney, pancreatic, and gastrointestinal problems. While effective in appetite and addiction control,

GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and gastrointestinal issues. Demand for weight-loss medications, including popular brands like Ozempic and Wegovy,

Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took researchers by surprise.

Over 2 million people were included in new research to test these drugs against 175 different health outcomes.

"All these years I thought that thin people -- those people -- just had more willpower," Winfrey said on her podcast.

Oprah Winfrey says taking a GLP-1 drug such as Ozempic and Wegovy has changed her entire perspective on “thin people.” The media icon, 70, took to her podcast last week to share her experience with an undisclosed type of GLP-1 drug that she began taking in 2023.

In a discussion with Oprah, Dr Ania called obesity a disease. She also advised that we should treat obesity like other medical conditions.

Oprah Winfrey shared that weight-loss medications like Ozempic and Wegovy helped her understand the challenges of being thin. After losing nearly 50 pounds, she emphasized that these drugs assist in managing cravings and support a healthier lifestyle amidst her struggles with weight.